{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T20:03:09Z","timestamp":1784404989369,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijgc.2025.102841","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:11:25Z","timestamp":1765422685000},"page":"102841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing nab-paclitaxel and solvent-based paclitaxel in platinum-resistant ovarian cancer: evidence and perspectives"],"prefix":"10.1016","volume":"36","author":[{"given":"Jalid","family":"Sehouli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan R.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0873-4686","authenticated-orcid":false,"given":"Jolijn D.","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek P.","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8754","authenticated-orcid":false,"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Fechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8373-8569","authenticated-orcid":false,"given":"Giorgio","family":"Bogani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6891-7988","authenticated-orcid":false,"given":"Elena","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-9645","authenticated-orcid":false,"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8349-8224","authenticated-orcid":false,"given":"Chisato","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Krannich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Krull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":false,"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclten","family":"Oskay-\u00d6czelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-577X","authenticated-orcid":false,"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-2620","authenticated-orcid":false,"given":"Tobias","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijgc.2025.102841_bib1","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.3747\/co.21.1966","article-title":"Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations","volume":"21","author":"Boulanger","year":"2014","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102841_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11882-021-01014-x","article-title":"Drug desensitizations for chemotherapy: safety and efficacy in preventing anaphylaxis","volume":"21","author":"Caiado","year":"2021","journal-title":"Curr Allergy Asthma Rep"},{"issue":"32","key":"10.1016\/j.ijgc.2025.102841_bib3","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1200\/JCO.21.01200","article-title":"Do steroids matter? A retrospective review of premedication for taxane chemotherapy and hypersensitivity reactions","volume":"39","author":"Lansinger","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102841_bib4","article-title":"Ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer","year":"2025","journal-title":"NCCN Guidelines, version 1, 2025 National Comprehensive Cancer Network (NCCN)"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102841_bib5","article-title":"Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer","volume":"7","author":"Patel","year":"2022","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"10.1016\/j.ijgc.2025.102841_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13750-018-0115-5","article-title":"Online tools supporting the conduct and reporting of systematic reviews and systematic maps: a case study on CADIMA and review of existing tools","volume":"7","author":"Kohl","year":"2018","journal-title":"Environ Evid"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102841_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4103\/0253-7613.77341","article-title":"Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: an observational study","volume":"43","author":"Brahmachari","year":"2011","journal-title":"Indian J Pharmacol."},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2025.102841_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ygyno.2014.03.192","article-title":"Nanoparticle albumin-bound (nab) paclitaxel therapy in patients with primary and recurrent ovarian, fallopian tube, and primary peritoneal carcinoma","volume":"133","author":"Rasool","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102841_bib9","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2017.28.e38","article-title":"Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions","volume":"28","author":"Maurer","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102841_bib10","unstructured":"NCT05257408. Relacorilant in Combination With Nab-Paclitaxel in Advanced, platinum resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05257408. Published online 2022. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02381957\/full."},{"key":"10.1016\/j.ijgc.2025.102841_bib11","article-title":"Safety of nab-paclitaxel following an allergic reaction to paclitaxel: a single institution retrospective study","volume":"55","author":"Kochuveettil","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.ijgc.2025.102841_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4137\/CMO.S38204","article-title":"Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study","volume":"10","author":"Osman","year":"2016","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102841_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ygyno.2011.03.036","article-title":"A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"122","author":"Coleman","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"30","key":"10.1016\/j.ijgc.2025.102841_bib14","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.22.02624","article-title":"Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: a three-arm, randomized, controlled, open-label phase II study","volume":"41","author":"Colombo","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijgc.2025.102841_bib15","volume":"16","author":"Abraxane","year":"2025","journal-title":"European public assessment report (EPAR). European Medicines Agency (EMA)"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102841_bib16","first-page":"686","article-title":"Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane\u00ae) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer","volume":"14","author":"Saif","year":"2013","journal-title":"JOP"},{"key":"10.1016\/j.ijgc.2025.102841_bib17","article-title":"Infusion 100 mg\u201d Antitumor agent. Approved for Additional Indications of Gastric Cancer and Non-small Cell Lung Cancer","volume":"16","year":"2025","journal-title":"Taiho Pharmaceutical"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102841_bib18","article-title":"Nanoparticle albumin-bound paclitaxel and solvent-based paclitaxel as chemotherapy options for patients with advanced gastric cancer: a systematic review and meta-analysis","volume":"15","author":"Gangannapalle","year":"2023","journal-title":"Cureus"},{"issue":"18","key":"10.1016\/j.ijgc.2025.102841_bib19","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102841_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1568009615666150817121731","article-title":"Nab-paclitaxel in metastatic breast cancer: defining the best patient profile","volume":"16","author":"Gonz\u00e1lez-Mart\u00edn","year":"2016","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102841_bib21","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin Cancer Res."},{"issue":"22","key":"10.1016\/j.ijgc.2025.102841_bib22","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar","year":"2009","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ijgc.2025.102841_bib23","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102841_bib24","unstructured":"DiSaia PJ. The Gynecologic Oncology Group: 43 years of success. The Gynecologic Oncology Group. September 16, 2025. https:\/\/www.gog.org\/wp-content\/uploads\/2020\/02\/GOG-43rd-Anniversary-Pub.pdf."},{"key":"10.1016\/j.ijgc.2025.102841_bib25","article-title":"Target trial emulation: applying principles of randomised trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102841_bib26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial","volume":"2","author":"Shitara","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2025.102841_bib27","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1200\/jco.2010.28.15_suppl.5011","article-title":"A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer","volume":"28","author":"Benigno","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102841_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12094-019-02122-x","article-title":"First-line carboplatin\/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience","volume":"22","author":"Parisi","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102841_bib29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Participants of the fifth ovarian cancer consensus conference","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"issue":"10496","key":"10.1016\/j.ijgc.2025.102841_bib30","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.ijgc.2025.102841_bib31","first-page":"S1","article-title":"(GOG3073, ENGOTov72, APGOT-OV10): relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer previously exposed to a PARP inhibitor","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 7","key":"10.1016\/j.ijgc.2025.102841_bib32","article-title":"Second progression-free survival (PFS2) and subsequent treatment in patients with folate receptor alpha (FR\u03b1)-positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs investigator\u2019s choice chemotherapy: phase III MIRASOL trial","volume":"36","author":"Moore","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.ijgc.2025.102841_bib33","first-page":"S1","article-title":"Pembrolizumab versus placebo plus weekly paclitaxel \u00b1 bevacizumab in platinum-resistant recurrent ovarian cancer: results from the randomized double-blind phase III ENGOT-ov65\/KEYNOTE-B96 study","volume":"36","author":"Colombo","year":"2025","journal-title":"Ann Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T19:27:34Z","timestamp":1784402854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25019656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1048891X25019656"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102841","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing nab-paclitaxel and solvent-based paclitaxel in platinum-resistant ovarian cancer: evidence and perspectives","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"102841"}}